Literature DB >> 17913343

Delirium following abrupt discontinuation of fluoxetine.

Diana Blum1, José Maldonado, Everett Meyer, Maarten Lansberg.   

Abstract

Sudden discontinuation of serotonin reuptake inhibitors (SRI) can lead to a number of psychological (e.g., nervousness, anxiety, crying spells, psychomotor agitation, irritability, depersonalization, decreased mood, memory disturbances, confusion, decreased concentration, and/or slowed thinking) and somatic (e.g., nausea, dizziness, headache) symptoms. Recent studies have shown that withdrawal symptoms are common with paroxetine, venlafaxine and fluvoxamine, but relatively rare and mild with fluoxetine cessation, likely as a result of its longer half-life. We report an unusual case of a patient who developed delirium after abrupt discontinuation of fluoxetine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913343     DOI: 10.1016/j.clineuro.2007.08.016

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  5 in total

Review 1.  Identification and management of in-hospital drug-induced delirium in older patients.

Authors:  Angela G Catic
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

Review 2.  The preoperative neurological evaluation.

Authors:  John Probasco; Bogachan Sahin; Tung Tran; Tae Hwan Chung; Liana Shapiro Rosenthal; Zoltan Mari; Michael Levy
Journal:  Neurohospitalist       Date:  2013-10

Review 3.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

4.  Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review.

Authors:  Marcin Siwek; Adrian Andrzej Chrobak; Aleksandra Gorostowicz; Anna Julia Krupa; Dominika Dudek
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-11

5.  Delirium associated with discontinuation of sertraline in an elderly.

Authors:  Subhash Das; Mitesh Kumar; Alisha Sahotra
Journal:  Indian J Psychiatry       Date:  2019 Nov-Dec       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.